|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schoen RE, Pinsky PF, Weissfeld JL,
Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys
SS, Crawford ED, et al PLCO Project Team: Colorectal-cancer
incidence and mortality with screening flexible sigmoidoscopy. N
Engl J Med. 366:2345–2357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. John Wiley & Sons;
West Sussex: 2011
|
|
4
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
6
|
Dylla SJ, Beviglia L, Park IK, Chartier C,
Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S,
et al: Colorectal cancer stem cells are enriched in xenogeneic
tumors following chemotherapy. PLoS One. 3:e24282008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jensen NF, Stenvang J, Beck MK, Hanáková
B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, et
al: Establishment and characterization of models of chemotherapy
resistance in colorectal cancer: Towards a predictive signature of
chemoresistance. Mol Oncol. 9:1169–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Edhemovic I, Gadzijev EM, Brecelj E,
Miklavcic D, Kos B, Zupanic A, Mali B, Jarm T, Pavliha D, Marcan M,
et al: Electrochemotherapy: A new technological approach in
treatment of metastases in the liver. Technol Cancer Res Treat.
10:475–485. 2011.PubMed/NCBI
|
|
9
|
Martelli AM, Tazzari PL, Tabellini G,
Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R and Cocco L: A
new selective AKT pharmacological inhibitor reduces resistance to
chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and
ionizing radiation of human leukemia cells. Leukemia. 17:1794–1805.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schreiber R, Mezencev R, Matyunina LV and
McDonald JF: Evidence for the role of microRNA 374b in acquired
cisplatin resistance in pancreatic cancer cells. Cancer Gene Ther.
23:241–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li B, Zhao J, Wang C-Z, Searle J, He TC,
Yuan CS and Du W: Ginsenoside Rh2 induces apoptosis and
paraptosis-like cell death in colorectal cancer cells through
activation of p53. Cancer Lett. 301:185–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He ZY, Shi CB, Wen H, Li FL, Wang BL and
Wang J: Upregulation of p53 expression in patients with colorectal
cancer by administration of curcumin. Cancer Invest. 29:208–213.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mirzayans R, Andrais B, Scott A and Murray
D: New insights into p53 signaling and cancer cell response to DNA
damage: Implications for cancer therapy. J Biomed Biotechnol.
2012:1703252012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ng KW, Khoo SP, Heng BC, Setyawati MI, Tan
EC, Zhao X, Xiong S, Fang W, Leong DT and Loo JS: The role of the
tumor suppressor p53 pathway in the cellular DNA damage response to
zinc oxide nanoparticles. Biomaterials. 32:8218–8225. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YS, Yoon S, Park MS, Kim JH, Lee JH
and Song CW: Influence of p53 expression on sensitivity of cancer
cells to bleomycin. J Biochem Mol Toxicol. 24:260–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmittgen TD, Lee EJ, Jiang J, Sarkar A,
Yang L, Elton TS and Chen C: Real-time PCR quantification of
precursor and mature microRNA. Methods. 44:31–38. 2008. View Article : Google Scholar
|
|
17
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
eLife. 4:e050052015. View Article : Google Scholar :
|
|
18
|
Ma Z, Sun X, Xu D, Xiong Y and Zuo B:
MicroRNA, miR-374b, directly targets Myf6 and negatively regulates
C2C12 myoblasts differentiation. Biochem Biophys Res Commun.
467:670–675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suzuki HI and Miyazono K: Emerging
complexity of microRNA generation cascades. J Biochem. 149:15–25.
2011. View Article : Google Scholar
|
|
20
|
Guil S and Esteller M: DNA methylomes,
histone codes and miRNAs: Tying it all together. Int J Biochem Cell
Biol. 41:87–95. 2009. View Article : Google Scholar
|
|
21
|
Marsico A, Huska MR, Lasserre J, Hu H,
Vucicevic D, Musahl A, Orom U and Vingron M: PROmiRNA: A new miRNA
promoter recognition method uncovers the complex regulation of
intronic miRNAs. Genome Biol. 14:R842013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang CJ, Chao CH, Xia W, Yang JY, Xiong
Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al: p53 regulates
epithelial-mesenchymal transition and stem cell properties through
modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar
|
|
24
|
Jiang F-Z, He Y-Y, Wang H-H, Zhang HL,
Zhang J, Yan XF, Wang XJ, Che Q, Ke JQ, Chen Z, et al: Mutant p53
induces EZH2 expression and promotes epithelial-mesenchymal
transition by disrupting p68-Drosha complex assembly and
attenuating miR-26a processing. Oncotarget. 6:44660–44674.
2015.PubMed/NCBI
|
|
25
|
Gurtner A, Falcone E, Garibaldi F and
Piaggio G: Dysregulation of microRNA biogenesis in cancer: The
impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer
Res. 35:452016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Engels BM and Hutvagner G: Principles and
effects of microRNA-mediated post-transcriptional gene regulation.
Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qian D, Chen K, Deng H, Rao H, Huang H,
Liao Y, Sun X, Lu S, Yuan Z, Xie D, et al: MicroRNA-374b suppresses
proliferation and promotes apoptosis in T-cell lymphoblastic
lymphoma by repressing AKT1 and Wnt-16. Clin Cancer Res.
21:4881–4891. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bates S and Vousden KH: Mechanisms of
p53-mediated apoptosis. Cell Mol Life Sci. 55:28–37. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuribayashi K, Finnberg N, Jeffers JR,
Zambetti GP and El-Deiry WS: The relative contribution of
pro-apoptotic p53-target genes in the triggering of apoptosis
following DNA damage in vitro and in vivo. Cell Cycle.
10:2380–2389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dihlmann S, Kloor M, Fallsehr C and von
Knebel Doeberitz M: Regulation of AKT1 expression by
beta-catenin/Tcf/Lef signaling in colorectal cancer cells.
Carcinogenesis. 26:1503–1512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Green BD, Jabbour AM, Sandow JJ, Riffkin
CD, Masouras D, Daunt CP, Salmanidis M, Brumatti G, Hemmings BA,
Guthridge MA, et al: Akt1 is the principal Akt isoform regulating
apoptosis in limiting cytokine concentrations. Cell Death Differ.
20:1341–1349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tucka J, Yu H, Gray K, Figg N, Maguire J,
Lam B, Bennett M and Littlewood T: Akt1 regulates vascular smooth
muscle cell apoptosis through FoxO3a and Apaf1 and protects against
arterial remodeling and atherosclerosis. Arterioscler Thromb Vasc
Biol. 34:2421–2428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jackson JG, Pant V, Li Q, Chang LL,
Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et
al: p53-mediated senescence impairs the apoptotic response to
chemotherapy and clinical outcome in breast cancer. Cancer Cell.
21:793–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen GX, Zheng LH, Liu SY and He XH:
rAd-p53 enhances the sensitivity of human gastric cancer cells to
chemotherapy. World J Gastroenterol. 17:4289–4297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gu J, Tang Y, Liu Y, Guo H, Wang Y, Cai L,
Li Y and Wang B: Murine double minute 2 siRNA and wild-type p53
gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer
cell line to cisplatin chemotherapy in vitro and in vivo. Cancer
Lett. 343:200–209. 2014. View Article : Google Scholar
|
|
36
|
Guo L, Wu H, Zhu J, Zhang C, Ma J, Lan J
and Xie X: Genetic variations in the PI3K/AKT pathway predict
platinum-based neoadjuvant chemotherapeutic sensitivity in squamous
cervical cancer. Life Sci. 143:217–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
